Metrics as of 10/15/2026, 02:09 PM (Berlin time), refresh in progress.
Bioventix Stock
Bioventix PLC
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Peter John Harrison
- Employees
- 12
- Market cap
- £90 M
- IPO
- 29/04/2014
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health…
Bioventix stock: price history
1D
-1.7%
1W
-1.7%
1M
+14.7%
6M
-3.1%
YTD
-9.7%
1Y
-28.3%
2Y
-54.7%
5Y
-56.2%
10Y
+18.6%
Next earnings date
Next earnings date
26/10/2026 (in 9 days)
Volatility around earnings
~111% stronger price swings than usual
Ask the agents about Bioventix
Bioventix stock metrics
P/E
12.11
P/B
8.14
EV/EBITDA
8.86
RETURN ON EQUITY
32.8%
NET MARGIN
58.9%
DEBT/EQUITY
0
DIVIDEND YIELD
8.7%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
79.5%
FLOAT SHARES
4,154,586
AVG. DAILY VOLUME (30D)
13,332
Dividends
Comparable stocks
Frequently asked questions about Bioventix stock
What does Bioventix do?
Bioventix PLC is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Peter John Harrison, the company employs around 12 people.
The IPO was on 29/04/2014; the stock trades on LSE under the ticker BVXP.L.
When does Bioventix report next?
The next earnings date is 26/10/2026.
Around past earnings, price swings were roughly 111% stronger than usual.
Does Bioventix pay a dividend?
Yes. The last dividend was £70.00 per share, ex-date 09/04/2026, paid on 24/04/2026.
The dividend yield is 8.7% (as of 31/12/2025).
Which stocks are comparable to Bioventix?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Bioventix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bioventix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.